Pluri Inc - PLUR STOCK NEWS

Pluri Inc. (PLUR) announces a collaboration with Bar-Ilan University's BIRAD, funded by the Israel Innovation Authority, to advance cancer immunotherapy using Placental Mucosal Associated Invariant T (MAIT) cells for solid tumors. The partnership combines Pluri's proprietary MAIT cell expansion platform with Prof. Cyrille Cohen's Siglec-based Chimeric Switch Receptors technology to enhance CAR-MAIT's efficacy and tumor specificity. The project aims to develop innovative allogeneic cell therapies targeting solid tumors, addressing a significant unmet medical need. Pluri's MAIT cells, derived from human placentas, offer unique advantages including potency, multiple tumor-targeting mechanisms, and reduced risk of Graft versus Host Disease.

Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) has signed a tech transfer and manufacturing agreement with Kadimastem (TASE: KDST) through its PluriCDMO™ division. PluriCDMO™ will manufacture two cell therapy product candidates for Kadimastem: AstroRx® for ALS treatment and IsletRx for diabetes treatment. This collaboration leverages Pluri's 47,000 square foot GMP cell production facility and expertise in developing and manufacturing cell-based products. The agreement supports Kadimastem's preparation for clinical trials and expansion into the U.S. market, particularly for an upcoming FDA Phase 2a study of AstroRx®. This partnership highlights PluriCDMO™'s versatility and commitment to advancing innovative life-saving therapies.

Pluri has entered a €1 million proof of concept (POC) agreement with an international agriculture The collaboration aims to boost global vegetable supply, shorten supply chains, and promote sustainable agriculture. Pluri’s 3D cell expansion technology and the partner's market expertise will work together to minimize environmental impact and enhance food security. This initiative aligns with Pluri's strategy to partner with global companies and generate revenue through innovative projects. The global vegetable farming market, valued at $1.3 trillion, is projected to grow to $1.6 trillion by 2029, driven by a rising global population.

Pluri's subsidiary, Ever After Foods, has secured $10 million in strategic investments from U.S. and EU investors, including Tnuva Group. This funding aims to tackle scalability challenges in cultivated food production. Ever After Foods' innovative platform can produce cultivated meat, fish, and seafood with significant cost-efficiency, reducing production costs by over 90% and increasing protein and lipid yields substantially.

Leveraging Pluri's technology, Ever After Foods aims to expand its global market presence. The technology enables natural production of muscle and fat tissues, ensuring taste and texture akin to conventional meat. The new funding will also broaden Ever After Foods' scope to include cultivated fish, reinforcing its position as a leading technology enabler in the food industry.

Pluri announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has exercised a $1.4 million second-year funding option for a contract to develop PLX-R18, a cell therapy for Acute Radiation Syndrome (H-ARS). The contract, part of a $4.2 million three-year agreement, supports manufacturing, in vitro, and in vivo studies for PLX-R18. The therapy aims to counteract hematopoietic complications from ionizing radiation. Significant survival rate increases in both animal and human studies have been reported. PLX-R18 has also received FDA Orphan Drug Designation.

Pluri (Nasdaq: PLUR) has announced a strategic partnership with Wilk Technologies to create a medical food product derived from human breast milk for the elderly. This innovative product utilizes Pluri's 3D cell-expansion technology in combination with Wilk's cell-cultured milk components. The global elderly nutrition market, valued at $25.2 billion, is projected to reach $39.7 billion within the next decade. This collaboration aims to meet the unique nutritional needs of seniors, enhancing their quality of life while addressing age-related health concerns and chronic illnesses.

Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.

Pluri Inc. unveils a groundbreaking method for expanding immune cells using proprietary technology, securing a new U.S. patent. The innovative 3D cell expansion technology mimics the natural lymph node environment, ensuring the integrity and functionality of immune cells. This advancement positions Pluri at the forefront of allogeneic cell therapy, promising significant therapeutic advancements and commercial success. The estimated total addressable market for immune cell engineering is projected to grow to $11.66 billion by 2030.

Pluri Inc. announces participation in various conferences to showcase its innovative cell-based solutions and business verticals. The company's leadership will present at MIW, ATiO Conference 2024, Biomed Israel, and Bio International Convention, highlighting advancements in 3D cell expansion technology, cell-based coffee business, and PLX-PAD therapy product.